TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06260514
Drug: APR-1051
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEE1 Inhibitor
Study: NCT05557409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken twice daily
Study: NCT06433362
Drug: CMOEP
Normalized name: Chlormethine oxide ethyl phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 3 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1,every 3 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 3 mg/m2, the maximum dose of 4mg),every 3 weeks; Drug: Etoposide Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3,every 3 weeks;
Study: NCT04767542
Drug: Intravenous Infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: analgesic
Study: NCT06441006
Drug: Control Arm FQ-S MDR/RR-TB regimen, designed according to latest WHO guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 26 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest WHO guidelines and the local SOC.
Study: NCT05500508
Drug: AMXT1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules
Study: NCT06462404
Drug: E2086 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2086 matching placebo tablet.
Study: NCT04609046
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT06093191
Drug: Tobramycin Inhalant Product
Normalized name: tobramycin Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Study: NCT06093191
Drug: Natural saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Study: NCT06427980
Drug: Chinese Herbal formula HuoXue LiShui
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of the oral administration of granule with either HXLS or a placebo substance, one bag (28.5 g) twice daily after meals for a period of 8 weeks. The granules are produced from four Chinese herbal pieces: Yi Mu Cao (Leonuri Herbal, 15.0g), Zhi Shui Zhi (Hirudo, 1.5g), Tao Ren (Semen persicae, 6.0g), and Hong Hua (Carthami Flos, 6.0g).
Study: NCT06427980
Drug: Chinese Herbal formula Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be consistent with the HXLS oral granules in appearance, taste, and weight, to the greatest extent possible. In terms of outer packing, the HXLS and placebo granules will be exactly the same. It included Hu Jing (28.5g)
Study: NCT05135286
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single drop in each eye at a visit.
Study: NCT06639256
Drug: Test Product HY07121
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HY07121 should be administered intravenously at recommended dose.
Study: NCT06228846
Drug: YY001
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'YY001'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04984876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection once every 4 weeks
Study: NCT06155825
Drug: oral glucose 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 will receive oral glucose 25%
Study: NCT06637137
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
Study: NCT05526144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
Study: NCT06637371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection
Study: NCT05452239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT06639997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Study: NCT05777369
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2, d1
Study: NCT05239741
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 given as an IV on Day 1 Q2W as part of the mFOLFOX6 and FOLFIRI regimens
Study: NCT05715788
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhalation at 20 ppm
Study: NCT04682106
Drug: LY3493269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04682106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04682106
Drug: Salcaprozate Sodium
Normalized name: Salcaprozate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05781243
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.
Study: NCT05440734
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 Mg Oral Tablet, slow release
Study: NCT06210971
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 625mg/m\^2 or 1000mg/m\^2 bid.
Study: NCT06084104
Drug: DZD9008
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 200mg DZD9008
Study: NCT05145569
Drug: HCW9218
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCW9218 is an immunotherapeutic comprising transforming growth factor-b (TGF-b) receptor II and interleukin (IL)-15/IL-15 receptor a domains.
Study: NCT06352437
Drug: Placebo matching BI 3034701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 3034701
Study: NCT06091254
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV as part of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) chemotherapy, or Cyclophosphamide, Vincristine, Prednisone (CVP) chemotherapy
Study: NCT06091254
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV as part of CHOP chemotherapy
Study: NCT06221059
Drug: HRS-1780 tablet；Henagliflozin Proline tablet；HRS-1780 tablet placebo ；Henagliflozin Proline tablet placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug：HRS-1780 tablet Drug：Henagliflozin Proline tablet Drug：HRS-1780 tablet placebo Drug：Henagliflozin Proline tablet placebo
Study: NCT05818111
Drug: steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone 40mg 4cc
Study: NCT05818111
Drug: Xylocaine 2 % Injectable Solution
Normalized name: Xylocaine 2 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylocaine 2% 4cc
Study: NCT05549323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06357234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of dextrose syrup (2ml). One to be given on the morning of surgery and the second on the morning of post-op day 1
Study: NCT06184321
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instilled into IPC
Study: NCT06617546
Drug: FTX-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder for subcutaneous injection
Study: NCT06617546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder for subcutaneous injection
Study: NCT05092841
Drug: PXT3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered PXT3003 twice daily (bid) at 10mL.
Study: NCT05092841
Drug: PXT3003 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
Study: NCT06484816
Drug: TGRX-1942
Approvals — FDA: no, EMA: no, PMDA: no
Description: At dose escalation phase, TGRX-1942 will be given orally to patient once a day under a 7-dose sequence of 4mg, 10mg, 20mg, 30mg, 40mg, 50mg, and 60mg. The dose level a particular patient will be assigned depends on the progression of the study and PI evaluation on the safety of previous dose group(s).
Study: NCT04917029
Drug: Dexmedetmidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: infusion of Dexmedetmidine 0.5 µg/kg/h
Study: NCT06391931
Drug: Cipepofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain
Study: NCT05336721
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 on Days 1-14 in a repeating 21-day cycle
Study: NCT04804072
Drug: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOUD for OUD
Study: NCT04804072
Drug: HIV treatment for participants living with HIV not already in care
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV treatment for participants living with HIV not already in care
Study: NCT04804072
Drug: PrEP for participants without HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP for participants without HIV
Study: NCT06418529
Drug: tumor necrosis factor inhibitors (TNFi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New index treatment of TNFi
Study: NCT05067517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized in a 1:1 ratio to either oral nintedanib 150 mg (n=80) or matching placebo (n=80) twice daily.
Study: NCT00989807
Drug: Aztreonam lysine
Normalized name: aztreonam lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
Study: NCT04768569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
Study: NCT04489160
Drug: C1 Inhibitor, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6000 IU C1-INH
Study: NCT04489160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline
Study: NCT05092802
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg bid po
Study: NCT06252506
Drug: N,N-dimethyltryptamine (DMT) + harmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT and harmine are the two most abundant chemicals in the Amazonian hallucinogenic plant brew, Ayahuasca, which is used traditionally in spiritual and healing ceremonies. An oral formulation of these two substances will be tested against placebo in the context of an FDG-PET scan.
Study: NCT06252506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered on one of the study days to compare the effects of DMT and harmine with the effects a placebo administration.
Study: NCT04830397
Drug: QLS-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution 1x daily
Study: NCT06268574
Drug: RVU120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Study: NCT06260709
Drug: NNC6019-0001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
Study: NCT05832151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules twice daily for 12 weeks
Study: NCT05028062
Drug: XR-NTX 380 mg, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of XR-NTX 380 mg, intramuscular injection.
Study: NCT05028062
Drug: Placebo intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of XR-NTX 380 mg, intramuscular injection.
Study: NCT06402838
Drug: RO7269162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
Study: NCT06402838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive daily doses of placebo for up to 72 weeks.
Study: NCT05671835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally via a tablet.
Study: NCT06568471
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00705796
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AndroGel® 50 mg, once daily in the morning after washing/showering.
Study: NCT05403281
Drug: DW6012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Study: NCT05068102
Drug: [89Zr]Zr- BI 770371
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[89Zr\]Zr- BI 770371, specifically radiolabelled for immune-PET
Study: NCT06568549
Drug: Mycophenolate Mofetil (MMF) Maintenance Group
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
Study: NCT06568549
Drug: Mycophenolate Mofetil (MMF) Withdrawal Group
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
Study: NCT05212246
Drug: Placebo Vehicle Control Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo vehicle control cream will be a virtually identical cream (to the Imiquimod cream) that contains no Imiquimod. This cream will be applied once daily to the face in a thin layer for 12 weeks. Three packets of cream will be defined as one dose or application. The cream should be applied to the face prior to normal sleeping hours (it is readily absorbed) and left on the skin for 6-10 hours (i.e. overnight). Rest periods will be allowed if bothersome side effects occur.
Study: NCT06568588
Drug: S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg three times a day for 4 months
Study: NCT05661201
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
Study: NCT05026177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given b.i.d. for 76 weeks
Study: NCT05911425
Drug: envolizumab , sovalteinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.
Study: NCT06779435
Drug: Conventional immunochemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks
Study: NCT06525935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
Study: NCT06527365
Drug: VDPHL01
Approvals — FDA: no, EMA: no, PMDA: no
Description: VDPHL01 Extended Release (ER) Tablet
Study: NCT04406857
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05113251
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered by intravenous infusion
Study: NCT05113251
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered by intravenous infusion
Study: NCT05999799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT03673735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (one dose) before CRT and for 6 months Q4W after CRT
Study: NCT05244980
Drug: TDM-105795
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM-105795 topical solution
Study: NCT05244980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for TDM-105795 topical solution
Study: NCT05799378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine-matching placebo capsule. Administered orally.
Study: NCT05597878
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
Study: NCT05597878
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
Study: NCT05597878
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
Study: NCT05884333
Drug: Conditioning Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
Study: NCT06219941
Drug: AZD0901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-drug conjugate/Biologic
Study: NCT06219941
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy agents
Study: NCT06219941
Drug: l-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy agents
Study: NCT06346509
Drug: PORT-77
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy adult participants will receive a single oral dose of PORT 77.
Study: NCT06346509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy adult participants will receive matching placebo on Day 1.
Study: NCT05940571
Drug: MBF-362
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles
Study: NCT05742061
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The injection will be given at a site near the superolateral pole of patella in the suprapatellar pouch under aseptic conditions and the patient will be advised to take one day of rest after injection and apply ice to the area if there are any signs of inflammation.
Study: NCT05287113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously.
Study: NCT05692492
Drug: ZSP1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg BID
Study: NCT05692492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05222802
Drug: ERAS-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06079190
Drug: GSK4527226
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4527226 will be administered.
Study: NCT06510764
Drug: Ziyinxiehuo Granules of traditional Chinese Medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziyinxiehuo Granules of traditional Chinese Medicine which includes shengdi 15g, xuanshen 9g, zexie 9g, zhimu9g, huangbai 9g, zhiguiban 9g, maiya 15g, tiandong 9g, zhigancao 9g,and will be administered after dissolved, 1package every time, 2 times per day after a meal.
Study: NCT05845398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline for injection.
Study: NCT05894694
Drug: first-line scheme+compound kushen injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
Study: NCT05894694
Drug: palliative care group first-line scheme
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab